Welcome to our dedicated page for Nurexone Biologic news (Ticker: NRXBF), a resource for investors and traders seeking the latest updates and insights on Nurexone Biologic stock.
NurExone Biologic Inc (NRXBF) is a pioneering biotechnology company advancing regenerative medicine through exosome-based therapies for tissue repair and targeted drug delivery. This page provides investors and industry observers with essential updates on clinical developments, strategic initiatives, and operational milestones.
Access consolidated news about NRXBF's progress in validating its proprietary exosome Platform, including preclinical studies and manufacturing advancements. Track updates on therapeutic candidates like ExoPTEN, designed to address neurological and ocular conditions through minimally invasive approaches.
Key content includes earnings announcements, partnership disclosures, research breakthroughs, and regulatory developments. All materials are sourced directly from verified company communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to NurExone's latest advancements in siRNA production, GMP-compliant manufacturing, and collaborative research efforts shaping the future of regenerative therapies.
NurExone Biologic (NRXBF) has announced breakthrough findings in facial nerve regeneration using their ExoPTEN therapy, marking their third therapeutic indication alongside spinal cord injury and optic nerve regeneration programs. Preclinical studies demonstrated significant functional recovery in facial nerve injury models, potentially addressing conditions like Bell's palsy and Ramsay Hunt Syndrome.
The research, conducted at the Israel Institute of Technology, validates PTEN downregulation as a strategy for axon regrowth. The therapy could target a market where approximately 30% of patients experience long-term functional impairment. The company's ExoTherapy platform utilizes exosomes for precise, minimally-invasive delivery of treatments to injured tissues.
NurExone is preparing an Investigational New Drug (IND) application for ExoPTEN in acute spinal cord injury. The technology is protected by a U.S. patent owned by the Technion, with worldwide exclusive licensing to NurExone, and has been granted in Japan, Russia, and Israel.
NurExone Biologic (TSXV: NRX) (OTCQB: NRXBF) has appointed Jacob Licht as CEO of Exo-Top Inc., its wholly owned subsidiary, and as Vice President of Corporate Development. Exo-Top will serve as a U.S.-based GMP-compliant exosome manufacturing facility, important for NurExone's global supply chain and commercialization strategy.
Licht brings over 20 years of biotech and specialty pharmaceuticals experience, having led transactions worth $1 billion across mergers, acquisitions, licensing, and asset sales. His previous roles include VP positions at Lantheus Medical Imaging, Bavarian Nordic, and Emergent BioSolutions.
Additionally, NurExone has completed its continuance from Alberta to Ontario, following shareholder approval at its June 3, 2024 meeting.
NurExone Biologic (NRXBF) reported its Q4 and full-year 2024 financial results, highlighting progress in its ExoPTEN therapy development for acute Spinal Cord Injury. The company's net loss widened to US$5.04M in 2024 from US$3.64M in 2023, with Q4 2024 net loss at US$1.55M.
Key developments include advancement of ExoPTEN's regulatory pathway towards IND application, establishment of in-house laboratory facilities, and promising preclinical results for treating optic nerve damage. The company's cash position stood at US$0.70M as of December 31, 2024.
Financial highlights show R&D expenses increased to US$1.87M in 2024 (vs US$1.54M in 2023), while G&A expenses rose to US$3.14M (vs US$2.12M). The company recently closed an April 2025 Offering raising C$2.3M through private placement at C$0.65 per unit, with proceeds intended for working capital, U.S. production facility establishment, and planned uplisting to a major U.S. exchange.
NurExone Biologic has successfully closed a non-brokered private placement, raising C$2.3 million through the issuance of 3,543,238 units at C$0.65 per unit. Each unit includes one common share and one warrant, with warrants exercisable at C$0.85 per share for 36 months.
The company plans to utilize the proceeds for working capital, establishing an ExoTop U.S. production facility, and pursuing an uplisting to a major U.S. exchange, subject to regulatory approval. The securities issued are subject to a four-month and one-day statutory hold period.
NurExone Biologic Inc. (NRXBF) has completed a important preclinical study for its ExoPTEN treatment, marking progress toward IND submission and first-in-human trials. The study demonstrated that ExoPTEN significantly improved both motor function recovery and blood flow at spinal cord injury sites.
The research compared two dosing regimens: a single high dose on surgery day versus a lower dose over five consecutive days. Both groups showed notable improvements in motor function recovery compared to the control group, measured by the modified BBB locomotor rating scale. Histological analysis revealed increased average blood vessel size in treated subjects, indicating enhanced circulation important for tissue healing.
Dr. Tali Kizhner, Director of R&D at NurExone, highlighted that the results support ExoPTEN's potential to enhance natural repair mechanisms following spinal cord injury. The company will continue refining ExoPTEN's therapeutic profile as part of its ongoing preclinical program.
NurExone Biologic has been named to the prestigious 2025 TSX Venture 50™, standing out as the only biotech company among three life sciences firms selected. The company achieved remarkable performance metrics, including 110% share price appreciation and 209% market cap growth.
The TSX Venture 50™ recognition, which evaluates companies based on share price appreciation and market capitalization growth, selected NurExone from 1,605 listed issuers. The company's success is driven by significant progress in developing ExoPTEN, their proprietary exosome therapy for acute spinal cord injuries, and the establishment of their U.S. subsidiary, Exo-Top Inc., which enhances their exosome production capabilities.
The 2025 TSX Venture 50™ companies demonstrated an impressive average share price appreciation of 207%, with 80% of the selected companies operating internationally across Europe, South America, Africa, and beyond.
NurExone Biologic (TSXV: NRX) (OTCQB: NRXBF) has been selected to present at MIXiii 2025, Israel's premier Health Tech conference. The company will showcase preclinical results demonstrating significant optic nerve regeneration during the Innovation in Ophthalmology session.
The presentation will highlight research conducted at Tel Hashomer's Goldschleger Eye Institute, led by Professor Michael Belkin, who will receive the Lifetime Achievement Award at the conference. Professor Belkin, a key scientific advisory board member at NurExone, is notably the inventor of Belkin Vision technology, recently acquired by Alcon for up to $466 million.
NurExone is launching a new preclinical study using its lead product, ExoPTEN, on a large group of small animals to expand upon previous positive results in neurodegenerative eye disease treatment. The research aims to develop innovative treatments for currently untreatable eye conditions, particularly focusing on glaucoma and related disorders.
NurExone Biologic has been named to the 2025 TSX Venture 50™, a prestigious ranking of top-performing companies on the TSX Venture Exchange. The company stands out as the only biotech firm among three life sciences companies receiving this recognition, demonstrating its leadership in exosome-based therapies and regenerative medicine for central nervous system injuries.
The company achieved remarkable performance metrics, including 110% share price appreciation and 209% market cap growth. The TSX Venture 50™ selection process evaluated 1,605 listed issuers, with chosen companies showing exceptional performance across various metrics. In 2024, the selected companies averaged 207% share price appreciation.
Key achievements include progress in developing ExoPTEN, their proprietary exosome therapy for acute spinal cord injuries, and establishing U.S. subsidiary Exo-Top Inc. to enhance exosome production capabilities. The TSXV platform serves as a important foundation for early-stage, high-growth companies, with 80% of 2024's Venture 50™ companies operating internationally.
NurExone Biologic (TSXV: NRX) (OTCQB: NRXBF) has announced its upcoming presentation at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting in New Orleans from May 7-10, 2025. The company will showcase its innovative ExoPTEN therapy, presenting robust preclinical data that demonstrates significant improvements in motor and sensory functions in spinal cord injury animal models through minimally invasive treatment.
This presentation aligns with NurExone's U.S. expansion strategy, following the recent launch of its U.S. subsidiary, Exo-Top, which will focus on producing GMP-grade exosomes for both research and therapeutic applications. The company aims to supply these exosomes for its own product development and to third parties, strengthening its position in the U.S. market.
Dr. Tali Kizhner, Director of R&D, emphasized the importance of presenting to leading experts, while CFO Eran Ovadya highlighted how participation in prestigious events like ISCT 2025 supports their U.S. listing aspirations and strategy to increase shareholder value.
NurExone Biologic (TSXV: NRX) (OTCQB: NRXBF) has announced the formation of Exo-Top Inc., a U.S.-based subsidiary focused on GMP-grade exosome production. This strategic move follows NurExone's acquisition of a Master Cell Bank of Mesenchymal Stem Cells, providing a sustainable source for exosome production.
The new subsidiary will support NurExone's internal drug development and supply exosomes to pharmaceutical companies, biotech firms, and researchers worldwide, creating additional revenue streams. Exo-Top will operate independently without external licensing or royalty obligations, ensuring cost efficiency and strategic flexibility.
The company plans to pursue an uplisting from OTC to a major U.S. exchange, subject to regulatory approval. Established in Nevada, Exo-Top's U.S. location offers advantages including proximity to strategic partners and access to a robust biopharma ecosystem.
